drugset / Trial / NCT01246479

Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study

NCT01246479

Phase 3 Completed 23 enrolled Valneva Austria GmbH
NaSingle-groupOpen-labelOther

Summary

The study investigates long-term immunity and safety of IC51 (IXIARO®, JESPECT®) in a pediatric population vaccinated in the parent study IC51-322.

Timeline

Start
2010-10
Primary completion
2012-10
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Background IC51 Vaccine

Indications